The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Anbal-cel: a novel anti-CD19 CAR-T therapy with dual silencing of PD-1 & TIGIT for LBCL
Won-Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, South Korea, discusses a Phase I/II study evaluating anbalcabtagene autoleucel (anbal-cel), a novel anti-CD19 CAR-T cell therapy, in large B-cell lymphoma (LBCL). Prof. Kim briefly explains the mechanism of action of anbal-cel and the promise of this novel agent for the treatment of relapsed/refractory (R/R) disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
